We are live on ! Find out more
OGEN icon

Oragenics
OGEN

13 hedge funds and large institutions have $9M invested in Oragenics in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

8% more funds holding

Funds holding: 12 → 13 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

14% less capital invested

Capital invested by funds: $10.5M → $9M (-$1.46M)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
13
Holders Change
+1
Holders Change %
+8.33%
% of All Funds
0.35%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
2
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$24K
2
GC
Guggenheim Capital
Illinois
+$12K
3
Squarepoint
Squarepoint
New York
+$12K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$528K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$120K
3
Citadel Advisors
Citadel Advisors
Florida
-$17K

OGEN Hedge Fund Activity: Q3 2016 in Review

13 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Oragenics (OGEN) for Q3 2016, worth a combined $9M — down 14% from $10.5M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new OGEN positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $24K. The largest seller was Fidelity Investments, cutting an estimated $528K.

  • 13 institutional investors held Oragenics (OGEN) as of Q3 2016, up from 12 in Q2 2016.
  • Funds reported $9M of Oragenics stock for Q3 2016, down 14% quarter-over-quarter.
  • 2 funds opened new Oragenics positions in Q3 2016 and 1 closed out, a net change of +1 holder.
  • The largest Oragenics buyer in Q3 2016 was Goldman Sachs, an estimated $24K added.
  • The largest Oragenics seller in Q3 2016 was Fidelity Investments, an estimated $528K sold.

Based on aggregated 13F filings for Q3 2016.